Miami, FL – July 30, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on Glucose Health, Inc. (OTC Pink: GLUC).
An article in InvestorPlace last week instructed you to “Sell Overpriiced Novavax Stock While You Still Can”.
Novavax, Inc. (NASDAQ: NVAX), thanks to the Trump administrations Operation Warp Speed’s contribution of $1.6 billion into their coffers, shot up 3,400% from $4.00 to $140.00 per share since January. Prior to the coronavirus however, Novavax was a struggling company and the government had chosen five far more established companies to battle the virus.
AstraZeneca (NYSE: AZN),
Johnson & Johnson (NYSE: JNJ)
Merck (NYSE: MRK)
Moderna (NASDAQ: MRNA)
Pfizer (NYSE: PFE)
It also appears that Inovo Pharmaceuticals (NASDAQ: INO) is falling behind in the race to develop a Covid-19 Vaccine.
INO Stock is still up a whopping 700% for the year but as we get closer to a vaccine, the lagers will begin to fall. It’s possible that the pharmaceutical space, with the failure of some of the majors finding a cure, combined with Trump’s executive order on drug pricing and a potential democratic win in November could see the biggest bear market in years.
So where do you go to find value if not in, but around this space?
Have a look at Glucose Health, Inc. (OTC Pink: GLUC). Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition consumer retail category under the registered trademark GLUCODOWN®. GLUCODOWN® is infused with a special form of dietary fiber demonstrated in 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.
Glucose Health, Inc. (OTC Pink: GLUC) just announced record sales increases as more diabetic customer buy the beverage at Amazon, not surprisingly during the pandemic. GLUCODOWN® is also sold nationwide in-store at Walmart pharmacies (NYSE: WMT), now the third largest pharmacy retailer after Walgreens and CVS.
What are the sales of this company going to look like when the sales numbers from Amazon and Walmart are reflected in the Q2 and Q3 financial statements for GLUC?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.